Shanghai Fosun Pharma's subsidiary to buy GlaxoSmithKline plant

0 Comment(s)Print E-mail Xinhua, July 9, 2019
Adjust font size:

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. will spend up to 250 million yuan (36 million U.S. dollars) to buy GlaxoSmithKline's Suzhou pharmaceutical factory in east China, according to a Fosun statement released Tuesday.

The deal will allow YaoPharma Co., Ltd., Fosun's Chongqing unit, to acquire all production facilities and authorizations for the GSK plant's chronic hepatitis B drug lamivudine.

The factory achieved a revenue of 656.1 million yuan, with a net profit of 73.98 million yuan in 2018, according to the statement.

Fosun Pharmaceutical's shares closed 0.58 percent higher at 26.24 yuan on Tuesday.

Follow on Twitter and Facebook to join the conversation.
ChinaNews App Download
Print E-mail Bookmark and Share

Go to Forum >>0 Comment(s)

No comments.

Add your comments...

  • User Name Required
  • Your Comment
  • Enter the words you see:   
    Racist, abusive and off-topic comments may be removed by the moderator.
Send your storiesGet more from